ASCO Annual Meeting: Lung Cancer

An avelumab combination therapy shows promise against ALK-driven lung cancers, but another was neither safe nor effective in non–ALK-driven cases.

Cell-free DNA, used to guide treatment of advanced lung cancer, may become a tool for early detection, based on analysis of participants in the Circulating Cell-free Genome Atlas study.

Researchers in Hong Kong found dacomitinib was associated with longer OS than gefitinib in patients with advanced EGFR+ NSCLC.

In this video at ASCO 2018, James Mulshine, MD, discusses CMS coverage of low-dose CT lung cancer screening for selected Medicare beneficiaries, and clinical implications of early detection.

Weekly patient symptom self-reports, filed using an online tool, allowed timely detection of lung cancer relapses and prolonged patient survival.

Administering pembrolizumab before EGFR TKIs may be inappropriate for TKI-naive patients with EGFR-mutant NSCLC.

Alectinib was generally better tolerated and associated with better outcomes vs crizotinib in ALK mutation–positive non–small-cell lung cancer.

Combining the ALK inhibitor with this immunotherapeutic agent had an acceptable safety profile and yielded an ORR of 85.7%, South Korean investigators reported.

Obese patients survived longer during immune checkpoint blockade for metastatic lung cancer compared with underweight patients and those who lost weight during treatment.

Activating oncogene mutations do not predict lung tumor responses to immune checkpoint blockade, ImmunoTarget investigators found.

This video reviews pseudoprogression in non–small-cell lung cancer, including the incidence of this phenomenon and treatment considerations when it arises.

This video reviews the use of PD-L1 testing in selecting patients for frontline lung cancer treatment with pembrolizumab and examines which patients might not be appropriate for immunotherapy.

This video reviews immunotherapy options now available for the treatment of lung cancer across different lines of therapy.

This video highlights a study that tested an alternative maintenance strategy determined by response to induction chemotherapy for patients with advanced non-squamous non–small-cell lung cancer.

Treatment with nivolumab alone and in combination with ipilimumab resulted in durable responses in patients with previously treated small-cell lung cancer.

The use of prophylactic cranial irradiation (PCI) reduced the incidence of symptomatic and asymptomatic brain metastases in patients with radically treated stage III NSCLC. The therapy did not, however, improve overall survival, and decreased quality of life.

Lorlatinib exhibits durable responses in patients with ALK-positive non–small-cell lung cancer and robust intracranial activity in those with brain metastases.

Immunotherapy may represent an effective new treatment approach for relapsed mesothelioma patients, according to a new study.

Atezolizumab treatment beyond progression might benefit patients with advanced non–small-cell lung cancer, according to the first report from the randomized phase III OAK trial.

Dacomitinib delayed progression of EGFR-positive non–small-cell lung cancer, but led to more adverse events compared with gefitinib.

Ahead of the 2017 ASCO Annual Meeting, we discuss how to approach treatment for older patients with lung cancer.

Adjuvant gefitinib significantly prolonged time to recurrence compared with the standard of care for patients with NSCLC with EGFR-activating mutations.

The TKI brigatinib offered good response rates in a phase II trial of patients with ALK-positive non–small-cell lung cancer whose disease progressed on crizotinib.

A Web-based application allows for earlier detection of relapse among patients with advanced lung cancer, improving survival by 7 months.

Post-treatment CT surveillance does not offer better survival rates vs clinical symptoms evaluation for tumor recurrence in locally advanced non–small-cell lung cancer.

Testing for T790M mutations with plasma and urine assays can complement testing done from biopsy tissue in patients with EGFR TKI-resistant NSCLC.

The novel anti-PD-L1 agent avelumab showed some promising clinical activity and was generally well tolerated in a phase I trial of patients with unresectable, previously treated mesothelioma.

An antibody-drug conjugate, rovalpituzumab tesirine, shows promising efficacy against recurrent small-cell lung cancer.

A targeted-sequencing gene panel that includes EGFR, KRAS, PIK3CA, and other mutations from circulating tumor DNA detects stage I non–small-cell lung cancer and might outperform existing tumor markers.

Elderly patients with stage III non–small-cell lung cancer experience poorer overall survival than patients younger than age 70 years when treated with standard concurrent chemoradiotherapy, according to a pooled analysis.